Laura Rosiñol
University of Barcelona
429 Papers
1.5K Citations
Laura Rosiñol is an academic researcher from University of Barcelona. The author has contributed to research in topics: Multiple myeloma & Medicine. The author has an hindex of 55, co-authored 308 publications. Previous affiliations of Laura Rosiñol include National and Kapodistrian University of Athens & Hospital Universitario La Paz.
Chat about Author
Papers
Bortezomib/dexamethasone followed by autologous stem cell transplantation as front line treatment for light-chain deposition disease
Natalia Tovar,Ma Teresa Cibeira,Laura Rosiñol,Manel Solé,Carlos Fernández de Larrea,Lourdes Escoda,Montserrat Rovira,Joan Bladé +7 more
TL;DR: Three patients with LCDD treated with bortezomib/dexamethasone followed by high‐dose melphalan and autologous transplantation are described and it is believed that this new approach should be the treatment of choice in this disease.
33
Pattern of relapse and progression after autologous SCT as upfront treatment for multiple myeloma.
C. Fernández de Larrea,Raquel Jiménez,Laura Rosiñol,Eva Giné,Natalia Tovar,MT Cibeira,Francesc Fernández-Avilés,Cristina Martínez,M Rovira,J. Bladé +9 more
TL;DR: This study analyzed the type of relapse or progression, clinical features including the presence of extramedullary involvement and time to next treatment in 211 patients who underwent melphalan-based autologous SCT over an 18-year period at an institution.
33
Response to thalidomide in multiple myeloma: impact of angiogenic factors.
Laura Rosiñol,M. Teresa Cibeira,Marta Segarra,Maria C. Cid,Xavier Filella,Marta Aymerich,María Rozman,Leonor Arenillas,Jordi Esteve,Joan Bladé,Emili Montserrat +10 more
TL;DR: Thalidomide has antiangiogenic and immunomodulatory effects, mediated by several cytokines such as vascular endothelial growth factor (VEGF), fibroblastic growthFactor (FGF-2), hepatocyte growth factor(HGF), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha).
32
Thalidomide/Dexamethasone (TD) Vs. Bortezomib(Velcade®)/Thalidomide/Dexamethasone (VTD) Vs. VBMCP/VBAD/Velcade® As Induction Regimens Prior Autologous Stem Cell Transplantation (ASCT) in Younger Patients with Multiple Myeloma (MM): First Results of a Prospective Phase III PETHEMA/Gem Trial
Laura Rosiñol,M. Teresa Cibeira,Joaquín Martínez,Maria-Victoria Mateos,Ma José Terol,Javier de la Rubia,Luis Palomera,Felipe de Arriba,Albert Oriol,Adrian Alegre,Juan Besalduch,Raquel de Paz,José García-Laraña,Joaquín Díaz-Mediavilla,Anna Sureda,Juan José Lahuerta,J F San Miguel,Joan Bladé +17 more
TL;DR: The benefit of ASCT in MM is associated with the degree of tumour decrease with the initial induction chemotherapy, and the primary end points were response rate after induction and after ASCT and time to progression.
32
Clinical applicability and prognostic significance of molecular response assessed by fluorescent-PCR of immunoglobulin genes in multiple myeloma. Results from a GEM/PETHEMA study.
Joaquin Martinez-Lopez,Elena Fernández-Redondo,Ramón García-Sanz,Maria Angeles Montalbán,Pilar Martínez-Sánchez,Bruno Pavia,Maria-Victoria Mateos,Laura Rosiñol,Marisa Martín,Rosa Ayala,Rafael Martínez,María Jesús Blanchard,Adrian Alegre,Joan Besalduch,Joan Bargay,Miguel T. Hernandez,María Eugenia Sarasquete,Pedro Sánchez-Godoy,M. E. Fernández,Joan Bladé,Jesús F. San Miguel,Juan José Lahuerta +21 more
TL;DR: F‐PCR analysis is a rapid, affordable, and easily performable technique that, in some circumstances, may be a valid approach for minimal residual disease investigations in MM.
31